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Abstract
In mammals, sex differences in the adult brain are established very early in
development, when the brain is still very immature. In the case of having inherited
the SRY gene, during embryogenesis, testosterone secreted by the testes enters the
brain and is converted to estradiol by the aromatase. Then the estradiol acts by
binding to intracellular estrogen receptors (ERs) located predominantly in neurons,
masculinizing specific brain regions. But ERs are also transcription factors that,
when they are exposed to their ligand, dimerize and form complexes with
coactivator proteins and corepressors, modifying the transcription of multiple tar-
get genes in a cascade effect and ultimately neuronal function. Given the intimate
relationship between steroids and brain dimorphism, and steroid coactivators and
gene transcription, in the present work, we further explore the implication of ERs α
and β, and steroid coactivators NCoA-1, NCoA-2, NCoA-3, NCoA-4, NCoA-5 and
p300-CREBBP, in the genesis of brain dimorphism. Based on our data, we believe
that the coactivators NCOA-1, NCOA-2 and p300-CREBBP could be considered as
candidate genes for GI.
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1. Gender incongruence
The term gender identity refers to “a person’s innermost concept of self as male,
female, a blend of both or neither, how individuals perceive themselves and what
they call themselves” [1, 2], while sex refers to the biological sex characteristics
based on chromosomal, hormonal, physical, and anatomical characteristics.
Most people present an alignment of gender identity with natal sex (cisgender
individuals), but in some cases (transgender individuals) gender identity differs (in
varying degrees) from the sex assigned at birth. Thus, Gender Dysphoria (GD) in
the Diagnostic and Statistical Manual of Mental Disorders DSM-5 [3] or Gender
Incongruence (GI) in the International Classification of Diseases ICD-11 [4] are
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characterized by a marked incongruence between one’s experienced gender and the
sex assigned at birth.
2. The genetic and epigenetic basis of the gender incongruence
The origin of GI is complex and appears to be multifactorial. Current hypotheses
point out that GI could be associated with a characteristic neurodevelopmental
processes of the brain [5, 6], not concordant with gender, due to the influence of
testosterone, converted into estradiol in the brain.
Traditionally, this process of brain masculinization versus feminization, has been
exclusively analyzed from a hormonal perspective. But in the past two decades, it
has been found that this point of view is incomplete, since other important factors
such as epigenetics or genetics, for example, are not taken into account.
2.1 The genetic component
A genetic component should also be taken into account since different genes
start to express before the formation of the testes [7, 8]. In fact, in mammals, sexual
differentiation begins at the time of fertilization, through a different chromosomal
complement in males and females, and will be driven by the SRY gene, which will
guide the undifferentiated gonad towards the formation of the testes. Then, the
testosterone will masculinize specific regions of the brain, either directly, or indi-
rectly, through the action of the aromatase [9, 10].
Most studies about the genetic basis of GI analyzed the implication of some DNA
polymorphisms related to ERs, α and β, the AR, the aromatase CYP19A1 or the
CYP17A1 [11–20] as well as the interaction effects (epistasis) among them [15, 21].
A summary of the principal studies about the genetic component of GI is shown in
Table 1. This gene selection is based on the hypothesis that a small variation in the
DNA sequence of these genes would imply a high variability in the sensitivity of the
hormonal receptors to their ligands.
Henningsson et al. [11] were the first group to analyze three repeat polymor-
phisms, located in the estrogen receptor beta, the androgen receptor, and the
aromatase genes in a trans female population. They found a relationship between
the number of repetitions and gender incongruence. They found longer estrogen
receptor and androgen receptor polymorphisms in the trans female population.
Later, Hare et al. [12] replicated Henningsson’s study in a bigger population, finding
longer androgen receptor polymorphisms. However, when Ujike et al., [13] ana-
lyzed the same polymorphisms in a Japanese population, they did not find any
statistical difference. These and others polymorphisms were analyzed in a Spanish
population by our group. Our results confirmed the involvement of both estrogen
receptors (alpha and beta) in gender incongruence. Part of this data was confirmed
by Foreman et al. [15].
2.2 The epigenetic component
An epigenetic component may also be involved since there is evidence that some
environmental factors play a role in the sexual differentiation of the brain. For
example, in mice, the sex difference in maternal anogenital licking of male compared
with female pups produces a different methylation of the estrogen receptor α pro-
moter in the preoptic area [22]. And in humans, certain environmental factors, such
as a short crossover hormonal treatment (only 6 months), can modify the methyla-
tion profile of the estrogen receptor α promoter in a trans population [23, 24].
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3. Estrogens, androgens and their receptors and coactivators
3.1 Estrogens
Estradiol (E2) exerts a wide variety of effects on growth, development, the
function of reproductive systems and regulation in the central nervous system
[25, 26]. The mechanism of action of the two ER isoforms α and β consists of
binding with the E2 ligand to obtain the receptor’s dimerization (αα, αβ or ββ),
originating the necessary conformational changes in the ligand binding domain
(LBD) [27] and binding with high affinity to specific DNA sequences called estro-
gen response elements (EREs) [27] in the genes that are regulated by E2 (Figure 1).
This conformational change in the LBD allows coactivators and other co-regulating
proteins to be recruited. We must point out that this step is critical for the tran-
scriptional regulation of genes induced by E2 [28].
Furthermore, estrogens are produced in many regions of the brain including the
cortex, the hippocampus, the cerebellum, the hypothalamus and the amygdala,
among others [29]. The actions of estrogens in the developing brain are generally
permanent and range from the establishment of sexual differences to generalized
trophic and neuroprotective effects [30]. In addition, estrogens are an important
regulator of brain growth and differentiation, and ERs α and β are found in both the
developing [31] and the adult human brain [32].
Investigations Genes Populations
Henningsson et al. [11] ERβ, AR, CYP19A1 29 transwomen
Hare et al. [12] ERβ, AR, CYP19A1 112 transwomen
Ujikce et al. [13] ERβ, AR, CYP19A1 168 transmen
74 transwomen
Fernández et al. [14, 16] ERβ, AR, CYP19A1 273 transmen
442 transwomen
Bentz et al. [19] CYP17A1 49 transmen
104 transwomen
Fernández et al. [20] (2016) CYP17A1 223 transmen
317 transwomen






Fernández et al. [21] ERα, ERβ, AR, CYP19A 425 transmen
549 transwomen
Foreman et al. [15] AR, ERα, ERβ, SRD5A2, STS, SULT2A1, PGR,
COMT, CYP17, SRD5A2
380 transwomen
Fernández et al. [18] ERα:
rs9478245, rs3138774 rs2234693, rs9340799
226 transmen
273 transwomen
Aranda et al. [24] Epigenetics: ERα, ERβ, AR 12 transmen
6 transwomen
Fernández et al. [23] Epigenetics: ERα promoter 10 transmen
10 transwomen
Table 1.
Mean investigations about the genetic basis of gender incongruence.
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3.2 Estrogen and androgen receptors are transcription factors
We must point out that the packaging of DNA into chromatin causes a
general repression of gene activity, and transcription factors function to relieve
this chromatin-mediated repression [33].Thereby, once attached to their ligands,
the receptors dimerize, enter the nucleus, and interact with the promoter regions
of the target genes, modulating the expression of multiple genes in collaboration
with some steroid coactivators (Figure 1). In the case of the AR, its ligand
is androgen [34] while for the ERs, it is estrogen, 17β-Estradiol (E2) in
particular [26].
3.3 Steroid receptor coactivators
Proteins called SRCs (Steroid Receptor Coactivators) serve as primary
coactivators that interact with the complex formed by E2 and the hormonal recep-
tor. Additionally, SRCs recruit multiple secondary coactivators such as p300 and
the CREB-binding protein (also known as CREBBP) [35]. Both SRCs and p300 are
the first coactivators that are coupled to the E2-ER complex [36] to activate the
transcriptional process of the genes that are E2 targets (Figure 1).
Coactivators are proteins that influence the ability of the transcription factors to
activate or inhibit expression of multiple genes in a cascade mode [37]. Given the
intimate relationship between steroids and brain dimorphism, and coactivators and
gene transcription, and since ERs α-β and the AR are hormonal receptors that act as
transcription factors, it was clear that we should hypothesize the implication of
DNA coactivators in the process of GI.
Figure 1.
Molecular mechanisms of action of ERs α and β. hormone 17β-estradiol (E2) binds to the nuclear receptor
(ERα or ERβ), and after dimerization and translocation to the nucleus, the nuclear receptor complex binds
to a specific sequence of DNA known as an estrogen response element (ERE). The nuclear receptor




4. The role of E2-coactivators in the genetic basis of gender
incongruence
To our knowledge, no studies have been published about the role of steroid
receptor coactivators in the genetic basis of GI. Nevertheless, given the importance
of estrogens in GI, and the critical role of coactivators in the transcriptional gene
regulation induced by E2, our team deemed it interesting to analyze 247 single
nucleotide polymorphisms (SNPs) located at the coactivators NCoA-1(or SRC-1),
NCoA-2 (or SRC-2), NCoA-3 (or SRC-3), NCoA-4, NCoA-5 and p300-CREBBP, in
a transgender versus a cisgender population, because variation at the DNA level at
steroid receptor coactivators could affect the sensitivity of the E2-ER complex, and
consequently could modify the transcription of the genes regulated by E2. Some of
these data are being published, and the results of the whole study are presented in
this chapter.
4.1 The characteristics of the study
Genomic DNA was extracted from 94 Spanish transgender individuals (47
transmen and 47 transwomen) versus 94 Spanish cis gender individuals (44 cismen
and 50 ciswomen). The transgender population was diagnosed and recruited
through the Gender Unit of the Clínic Hospital of Barcelona (Spain) and the
cisgender population was selected from a country census (Pizarra) matching by
geographic origin and race.
We analyzed 247 polymorphisms distributed in the coactivators NCOA-1 (63
SNPs), NCOA-2 (64 SNPs), NCOA-3 (30 SNPs), NCOA-4 (4 SNPs), NCOA-5 (8
SNPs), p300 (9 SNPs) and CREBBP (69 SNPs) (Table 2), in a population of 94
Spanish transgender individuals versus 94 Spanish cisgender individuals, with the
same geographic origin, race and biological sex. All the polymorphisms were in
Hardy–Weinberg equilibrium.
4.2 The findings
4.2.1 Similar prevalence rates for the analyzed polymorphisms and comparison with the
global and European 1000 genomes
As expected, the prevalence rates for all analyzed polymorphisms in our popu-
lation were similar to those found in the Global 1000 genomes and the European
1000 genomes http://www.1000genomes.org (Table 3).
4.2.2 Eleven polymorphism showed differences in the distribution of the allele and
genotype frequencies
When we compared the distribution of the allele and genotype frequencies, we
found significant differences in 11 polymorphisms, that correspond to 4.45% of the
total analyzed: three polymorphisms located in NCOA-1, five in NCOA-2, two in
p300 and one in CREBBP (Tables 2 and 3). The description of the significant
association analyses with GI in different models of inheritance is in Table 4.
P1 polymorphism: The genotype T/T was overrepresented in the cis population
(P < 0.035 for dominant model) while the genotypes T/C-C/C were more frequent
in the trans population (OR = 2.12; P < 0.038). The genotype distribution was also
significant for the log-additive model (OR = 2.15; P < 0.027).
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P2 polymorphism: The genotype T/T was overrepresented in the cis population
(P < 0.044), while the genotypes T/G (OR = 1.97; P < 0.035) and G/G (OR = 2.65;





NCOA-1 2 The protein encoded by this gene acts as a
transcriptional coactivator for steroid and
nuclear hormone receptors.
63 3
NCOA-2 8 The encoded protein acts as an intermediary
factor for the ligand-dependent activity of
nuclear receptors, which regulate their target
genes upon binding of cognate response
elements.
64 5
NCOA-3 20 The protein encoded by this gene is a nuclear
receptor coactivator that interacts with nuclear
hormone receptors to enhance their
transcriptional activator functions.
30 0
NCOA-4 10 This gene encodes an androgen receptor
coactivator.
4 0
NCOA-5 20 This gene encodes a coregulator for the α and β
estrogen receptors.
8 0
p300 22 This gene encodes a transcriptional coactivator
protein.
9 2
CREBBP 16 This gene is ubiquitously expressed and is






Description of the analyzed polymorphisms.










NCOA-1 rs10495747 P1 T/C C = 0.11 C = 0.1330 C = 0.1153
rs2584940 P2 T/G G = 0.38 G = 0.4605 G = 0.4125
rs6756785 P3 A/G G = 0.32 G = 0.2115 G = 0.2883
NCOA-2 rs76968380 P4 G/A A = 0.06 A = 0.1138 A = 0.0646
rs34406737 P5 G/A A = 0.15 A = 0.1300 A = 0.1262
rs1963250 P6 G/T T = 0.57 T = 0.5691 T = 0.5368
rs10755950 P7 G/A A = 0.42 A = 0.5655 A = 0.4483
rs56055423 P8 A/G G = 0.05 G = 0.0132 G = 0.0457
p300 rs133084 P9 T/C C = 0.5956 C = 0.5447 C = 0.59
rs11806 P10 A/G G = 0.3894 G = 0.3499 G = 0.42
CREBBP rs2191416 P11 G/A A = 0.2660 A = 0.2555 A = 0.26
Table 3.
Description of the polymorphisms with significant differences.
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P < 0.045) were overrepresented in the trans population (codominant model). The
genotype distribution for P2 was also significant for the dominant and log-additive
models.
P3 polymorphism: The genotype A/A was overrepresented in the cis population
(P < 0.0079 for the dominant model), while the genotypes A/G-G/G were over-
represented in the trans population (OR = 2.20; P < 0.009). The genotype distri-
bution for P3 was significant for the codominant, dominant, overdominant and log-
additive models.
P4 polymorphism: The P4 polymorphism was only significant for the log-
additive model. The genotype G/G was overrepresented in the cis population, while
the genotypes G/A and A/A were overrepresented in the trans population
(OR = 2.57; P < 0.034 for the log-additive model).
P5 polymorphism: This polymorphism was significant for the codominant,
the recessive, and the overdominant models. The G/G and the A/A genotypes
were overrepresented in the trans population (P < 0.0029; codominant
model)) while the G/A was overrepresented in the cis population (OR = 0.48;
P < 0.036).
P6 polymorphism: The T/T genotype was overrepresented in the trans popula-
tion while the T/G and G/G were overrepresented in the cis population (OR = 0.42;
P < 0.008 for the dominant model). The genotype distribution was significant for
the codominant, dominant and log-additive models.
P7 polymorphism: This polymorphism was only significant for the recessive
model. The A/A genotype was overrepresented in the trans population (OR = 2.44;
P < 0.026, recessive model).
P8 polymorphism: The genotype A/A was overrepresented in the cis population
(P < 0.0068 dominant model) while the genotype A/G was overrepresented in the
trans population (OR = 4.49; P < 0.024, codominant model). This polymorphism
showed significant differences for the codominant, dominant, overdominant, and
log-additive models. Only the recessive model did not show significant results.
P9 polymorphism: The C/C genotype was overrepresented in the trans popula-
tion, while the T/C and T/T were overrepresented in the cis population (OR = 0.50;
P < 0.025, dominant model).
P10 polymorphism: This polymorphism was only significant for the log-additive
model. The G/G genotype was overrepresented in the trans population (OR = 2.69;
P < 0.030, codominant model).
P11 polymorphism: The A/A polymorphism was overrepresented in the trans
population (OR = 4.82; P < 0.048, recessive model), while G/G-A/G were more
frequent in the cis population (P < 0.025).
4.2.3 The three polymorphisms (P2, P9 and P10) showed significant differences in the
interaction analysis with the covariate “sex”
Furthermore, polymorphisms P2, P9 and P10 showed significant differences in
the interaction analysis with covariate “sex”. For the P2 polymorphism, the geno-
type T/G was more frequent in the trans population assigned as females at birth
than in the cis female population (OR = 2.76; P < 0.029) while the genotype G/G
was more frequent in the trans population assigned as males than in the cis male
population (OR = 8.0; P < 0.016).
While for the P9 polymorphism, the genotype T/T was more frequent in the cis
female population than in the trans population assigned as females at birth
(OR = 0.34; P < 0.014). And finally, the genotypes A/G-G/G for the P10 polymor-
phism were more frequent in the trans population assigned as females at birth than
in the cis female population (OR = 2.68; P < 0.031).
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Model Genotype Cis (%) Trans (%) OR P-value
P1 polymorphism (rs10495747)
Codominant T/T 79 (84%) 67 (71.3%) 1.00 0.068
T/C 15 (16%) 26 (27.7%) 2.04 (1.00–4.17) 0.05*
C/C 0 (0%) 1 (1.1%) NA (0.00-NA) —
Dominant T/T 79 (84%) 67 (71.3%) 1.00 0.035*
T/C-C/C 15 (16%) 27 (28.7%) 2.12 (1.04–4.32) 0.038*
Recessive T/T–T/C 94 (100%) 93 (98.9%) 1.00 0.24
C/C 0 (0%) 1 (1.1%) NA (0.00-NA) —
Overdominant T/T-C/C 79 (84%) 68 (72.3%) 1.00 0.051
T/C 15 (16%) 26 (27.7%) 2.01 (0.99–4.11) 0,054
Log-additive — — — 2.15 (1.07–4.29) 0.027*
P2 polymorphism (rs2584940)
Codominant T/T 43 (45.7%) 27 (28.7%) 1.00 0.044*
T/G 42 (44.7%) 52 (55.3%) 1.97 (1.05–3.70) 0.035*
G/G 9 (9.6%) 15 (16%) 2.65 (1.02–6.91) 0.045*
Dominant T/T 43 (45.7%) 27 (28.7%) 1.00 0.015*
T/G-G/G 51 (54.3%) 67 (71.3%) 2.09 (1.14–3.83) 0.017*
Recessive T/T–T/G 85 (90.4%) 79 (84%) 1.00 0.19
G/G 9 (9.6%) 15 (16%) 1.79 (0.74–4.33) 0.198
Overdominant T/T-G/G 52 (55.3%) 42 (44.7%) 1.00 0.14
T/G 42 (44.7%) 52 (55.3%) 1.53 (0.86–2.72) 0.148
Log-additive — — — 1.72 (1.10–2.69) 0.015*
P3 polymorphism (rs6756785)
Codominant A/A 50 (53.2%) 32 (34%) 1.00 0.029*
A/G 38 (40.4%) 54 (57.5%) 2.22 (1.21–4.08) 0.010*
G/G 6 (6.4%) 8 (8.5%) 2.08 (0.66–6.56) 0.213
Dominant A/A 50 (53.2%) 32 (34%) 1.00 0.0079*
A/G-G/G 44 (46.8%) 62 (66%) 2.20 (1.22–3.97) 0.009*
Recessive A/A-A/G 88 (93.6%) 86 (91.5%) 1.00 0.58
G/G 6 (6.4%) 8 (8.5%) 1.36 (0.45–4.10) 0.598
Overdominant A/A-G/G 56 (59.6%) 40 (42.5%) 1.00 0.019*
A/G 38 (40.4%) 54 (57.5%) 1.99 (1.11–3.55) 0.020*
Log-additive — — — 1.77 (1.10–2.87) 0.017*
P4 polymorphism (rs76968380)
Codominant G/G 88 (93.6%) 80 (85.1%) 1.00 0.075
G/A 6 (6.4%) 12 (12.8%) 2.20 (0.79–6.14) 0.132
A/A 0 (0%) 2 (2.1%) NA (0.00-NA) —
Dominant G/G 88 (93.6%) 80 (85.1%) 1.00 0.055
G/A-A/A 6 (6.4%) 14 (14.9%) 2.57 (0.94–7.00) 0.065
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Model Genotype Cis (%) Trans (%) OR P-value
Recessive G/G-G/A 94 (100%) 92 (97.9%) 1.00 0.095
A/A 0 (0%) 2 (2.1%) NA (0.00-NA) —
Overdominant G/G-A/A 88 (93.6%) 82 (87.2%) 1.00 0.13
G/A 6 (6.4%) 12 (12.8%) 2.15 (0.77–5.98) 0.144
Log-additive — — — 2.57 (1.01–6.55) 0.034*
P5 polymorphism (rs34406737)
Codominant G/G 63 (67%) 72 (76.6%) 1.00 0.0029*
G/A 31 (33%) 17 (18.1%) 0.48 (0.24–0.95) 0.036*
A/A 0 (0%) 5 (5.3%) NA (0.00-NA) —
Dominant G/G 63 (67%) 72 (76.6%) 1.00 0.14
G/A-A/A 31 (33%) 22 (23.4%) 0.62 (0.33–1.18) 0.142
Recessive G/G-G/A 94 (100%) 89 (94.7%) 1.00 0.0078*
A/A 0 (0%) 5 (5.3%) NA (0.00-NA) —
Overdominant G/G-A/A 63 (67%) 77 (81.9%) 1.00 0.018*
G/A 31 (33%) 17 (18.1%) 0.45 (0.23–0.88) 0.020*
Log-additive — — — 0.85 (0.49–1.49) 0.57
P6 polymorphism (rs1963250)
Codominant T/T 20 (21.3%) 37 (39.4%) 1.00 0.015*
T/G 54 (57.5%) 46 (48.9%) 0.46 (0.24–0.90) 0.021*
G/G 20 (21.3%) 11 (11.7%) 0.30 (0.12–0.74) 0.009*
Dominant T/T 20 (21.3%) 37 (39.4%) 1.00 0.0067*
T/G-G/G 74 (78.7%) 57 (60.6%) 0.42 (0.22–0.79) 0.008*
Recessive T/T–T/G 74 (78.7%) 83 (88.3%) 1.00 0.075
G/G 20 (21.3%) 11 (11.7%) 0.49 (0.22–1.09) 0.080
Overdominant T/T-G/G 40 (42.5%) 48 (51.1%) 1.00 0.24
T/G 54 (57.5%) 46 (48.9%) 0.71 (0.40–1.26) 0.245
Log-additive — — — 0.53 (0.34–0.83) 0.0043*
P7 polymorphism (rs10755950)
Codominant G/G 33 (35.1%) 31 (33%) 1.00 0.064
A/G 50 (53.2%) 40 (42.5%) 0.85 (0.45–1.62) 0.632
A/A 11 (11.7%) 23 (24.5%) 2.23 (0.93–5.31) 0.071
Dominant G/G 33 (35.1%) 31 (33%) 1.00 0.76
A/G-A/A 61 (64.9%) 63 (67%) 1.10 (0.60–2.01) 0.770
Recessive G/G-A/G 83 (88.3%) 71 (75.5%) 1.00 0.022*
A/A 11 (11.7%) 23 (24.5%) 2.44 (1.11–5.36) 0.026*
Overdominant G/G-A/A 44 (46.8%) 54 (57.5%) 1.00 0.14
A/G 50 (53.2%) 40 (42.5%) 0.65 (0.37–1.16) 0.14
Log-additive — — — 1.35 (0.90–2.04) 0.15
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Model Genotype Cis (%) Trans (%) OR P-value
P8 polymorphism (rs56055423)
Codominant A/A 91 (96.8%) 81 (86.2%) 1.00 0.021*
A/G 3 (3.2%) 12 (12.8%) 4.49 (1.22–16.49) 0.024*
G/G 0 (0%) 1 (1.1%) NA (0.00-NA) —
Dominant A/A 91 (96.8%) 81 (86.2%) 1.00 0.0068*
A/G-G/G 3 (3.2%) 13 (13.8%) 4.87 (1.34–17.69) 0.016*
Recessive A/A-A/G 94 (100%) 93 (98.9%) 1.00 0.24
G/G 0 (0%) 1 (1.1%) NA (0.00-NA) —
Overdominant A/A-G/G 91 (96.8%) 82 (87.2%) 1.00 0.012*
A/G 3 (3.2%) 12 (12.8%) 4.44 (1.21–16.29) 0.024*
Log-additive — — — 4.69 (1.32–16.63) 0.0057*
P9 polymorphism (rs133084)
Codominant C/C 27 (28.7%) 42 (44.7%) 1.00 0.056
T/C 46 (48.9%) 39 (41.5%) 0.55 (0.29–1.04) 0.066
T/T 21 (22.3%) 13 (13.8%) 0.40 (0.17–0.93) 0.034*
Dominant C/C 27 (28.7%) 42 (44.7%) 1.00 0.023*
T/C-T/T 67 (71.3%) 52 (55.3%) 0.50 (0.27–0.91) 0.025*
Recessive C/C-T/C 73 (77.7%) 81 (86.2%) 1.00 0.13
T/T 21 (22.3%) 13 (13.8%) 0.56 (0.26–1.19) 0.135
Overdominant C/C-T/T 48 (51.1%) 55 (58.5%) 1.00 0.3
T/C 46 (48.9%) 39 (41.5%) 0.74 (0.42–1.32) 0.307
Log-additive — — — 0.61 (0.41–0.93) 0.019*
P10 polymorphism (rs11806)
Codominant A/A 37 (39.8%) 25 (26.6%) 1.00 0.076
A/G 45 (48.4%) 49 (52.1%) 1.61 (0.84–3.08) 0.151
G/G 11 (11.8%) 20 (21.3%) 2.69 (1.10–6.58) 0.030*
Dominant A/A 37 (39.8%) 25 (26.6%) 1.00 0.055
A/G-G/G 56 (60.2%) 69 (73.4%) 1.82 (0.98–3.38) 0.058
Recessive A/A-A/G 82 (88.2%) 74 (78.7%) 1.00 0.08
G/G 11 (11.8%) 20 (21.3%) 2.01 (0.91–4.48) 0.086
Overdominant A/A-G/G 48 (51.6%) 45 (47.9%) 1.00 0.61
A/G 45 (48.4%) 49 (52.1%) 1.16 (0.65–2.06) 0.627
Log-additive — — — 1.63 (1.06–2.52) 0.023*
P11 polymorphism (rs2191416)
Codominant G/G 53 (57%) 47 (50%) 1.00 0.075
A/G 38 (40.9%) 38 (40.4%) 1.13 (0.62–2.05) 0.702
A/A 2 (2.1%) 9 (9.6%) 5.07 (1.04–24.67) 0.044*
Dominant G/G 53 (57%) 47 (50%) 1.00 0.34
A/G-A/A 40 (43%) 47 (50%) 1.32 (0.74–2.36) 0.354
Recessive G/G-A/G 91 (97.8%) 85 (90.4%) 1.00 0.025*
A/A 2 (2.1%) 9 (9.6%) 4.82 (1.01–22.93) 0.048*
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4.2.4 The haplotype analysis of the coactivators NCOA-1, NCOA-2 and p300, and
comparison between cis and trans population
The simultaneous analysis of multiple loci (haplotypes) was carried out in those
coactivators with two or more polymorphisms with statistical significance (NCOA-
1, NCOA-2 and p300) using logistic regression models.
4.2.4.1 Polymorphisms in NCOA-1
For the three polymorphisms located in NCOA-1 (Table 5), the T allele for P1
was linked to the T allele for P2, and to the A allele for P3 (haplotype 1: T–T-A) with
a total frequency of 0.45. This haplotype was more frequent in the cis than in the
trans population. The haplotype 5: C-G-A was overrepresented in the trans popula-
tion and showed statistical significance (OR = 2.62; P < 0.05). The P global haplo-
type association was P < 0.009.
4.2.4.2 Polymorphisms in NCOA-2
For the five polymorphisms located in NCOA-2 (Table 6), the significant hap-
lotypes were the haplotype 2: (G-G-T-A-A) (OR = 2.49; P < 0.02) and the haplo-
type 8: (G-G-T-A-G) (OR = 12.86; P < 0.028), with a P global haplotype association
P < 0.005. Both polymorphisms were overrepresented in the trans population.
4.2.4.3 Polymorphisms in p300
For the two polymorphisms located in p300 (Table 7), the significant haplotype
was haplotype 2 (T-A) (OR = 0.57; P < 0.018) with a P global haplotype association
P < 0.033. This haplotype was more frequent in the cis than in the trans population,
and it was only significant in the population with a female natal sex (biological sex)
(OR = 0.43; P < 0.013) (Table 8).
4.2.4.4 Summary of findings
In summary, when we analyzed the allele and genotype frequencies, we found
significant differences in 11 polymorphisms located in NCOA-1, NCOA-2, p300 and
CREBBP. Being the NCOA-2 and p300 the coactivators with the highest percent-
ages of polymorphisms with significant differences (5/64 and 2/9 respectively).
Furthermore, only P2 (located at NCOA-1), P9 (located at p300) and P10 (located
at p300) showed a different distribution of the genotypes in males and females, that
is, they showed significant differences in the interaction analysis with covariate
“sex”.
Regarding the haplotype analysis, there were four polymorphisms with
significant differences: the haplotype 5 (C-G-A) in NCOA-1, the haplotype 2
Model Genotype Cis (%) Trans (%) OR P-value
Overdominant G/G-A/A 55 (59.1%) 56 (59.6%) 1.00 0.95
A/G 38 (40.9%) 38 (40.4%) 0.98 (0.55–1.76) 0.951
Log-additive — — — 1.49 (0.92–2.41) 0.1
Table 4.
Polymorphism association analysis with gender incongruence, in different models of inheritance (Codominant,
Dominant, Recessive, Overdominant and Log-additive) (n = 188, crude analysis).
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Haplotype frequencies estimation and haplotype association with GI (n = 188, adjusted by sex)
Haplotypes P1 P2 P3 Total Cis population Trans population Cumulative frequency OR (95% CI) P-value
1 T T A 0.4501 0.5201 0.377 0.4501 1.00 —
2 T T G 0.1495 0.134 0.1699 0.5996 2.25 (0.99–5.13) 0.054
3 T G G 0.147 0.1319 0.1601 0.7466 1.73 (0.81–3.71) 0.16
4 T G A 0.139 0.1341 0.144 0.8856 1.80 (0.81–3.97) 0.15
5 C G A 0.069 0.0531 0.0897 0.9546 2.62 (1.00–6.83) 0.05*
6 C T A 0.0228 0.0267 0.0169 0.9774 1.39 (0.23–8.34) 0.72
7 C G G 0.0226 0 0.0423 1 379142884.10 (379142883.16–379142885.04) <0.0001*
*Global haplotype association P-value: 0.009.
Table 5.









Haplotype frequencies estimation and haplotype association with GI (n = 188, adjusted by sex)






OR (95% CI) P-value
1 G G G G A 0.2546 0.3239 0.1963 0.2546 1.00 —
2 G G T A A 0.2206 0.2142 0.236 0.4752 2.49 (1.16–5.34) 0.02*
3 G G T G A 0.2022 0.1721 0.2303 0.6773 2.00 (0.93–4.31) 0.079
4 G G G A A 0.0891 0.0861 0.0793 0.7664 1.05 (0.38–2.88) 0.92
5 G A G G A 0.0474 0.0656 0.0235 0.8138 0.55 (0.11–2.89) 0.48
6 G A T A A 0.0419 0.0474 0.0423 0.8557 1.11 (0.24–5.24) 0.89
7 G A T G A 0.041 0.0393 0.0426 0.8967 3.00 (0.10–86.09) 0.52
8 G G T A G 0.0217 0 0.036 0.9184 12.86 (1.34–123.38) 0.028*
9 A G T G A 0.0173 0.0085 0.0228 0.9357 5.62 (0.56–56.71) 0.15
10 A G G G A 0.0165 0.0077 0.0205 0.9522 3.53 (0.40–31.50) 0.26
11 G A T A G 0.0138 0.0028 0.0189 0.9659 2.68 (0.27–26.20) 0.4
12 A G T A A 0.0108 0.0158 0.0093 0.9767 0.00 (-Inf - Inf) 1




*Global haplotype association P-value: 0.005.
Table 6.











































(G-G-T-A-A) in NCOA-2, the haplotype 8 (G-G-T-A-G) also in NCOA-2, and the
haplotype 2 (T-A) in p300. These NCOA-1 and NCOA-2 significant haplotypes
were more frequent in the trans population (OR = 2.62, OR = 2.49 and OR = 12.86,
respectively) while the haplotype 2 (T-A) in p300 was more frequent in the cis
population (OR = 0.57). The NCOA-2 haplotype 8 (OR = 12.86; P < 0.028) had a
Haplotype frequencies estimation and Haplotype association with GI (n = 188, adjusted by sex)










1 C G 0.4103 0.3468 0.4734 0.4103 1.00 —
2 T A 0.4004 0.4549 0.3457 0.8107 0.57 (0.36–
0.90)
0.018*
3 C A 0.1828 0.1851 0.1809 0.9935 0.69 (0.38–
1.27)
0.24
4 T G 0.0065 0.0132 0 1 0.00 (-Inf -
Inf)
1
*Global haplotype association P-value: 0.033.
Table 7.
Haplotype analysis for polymorphisms located in p300 (P9 and P10 polymorphisms).
Haplotype and sex cross-classification interaction table (n = 188, crude analysis)
Females Males
Haplotype Frequency OR (95% CI) P-value OR (95% CI) P-value
1 0.4102 1.00 — 0.63 (0.19–2.07) 0.457
2 0.4003 0.43 (0.22–0.83) 0.013* 0.49 (0.19–1.27) 0.141
3 0.1829 0.60 (0.26–1.40) 0.237 0.52 (0.18–1.52) 0.232
Rare 0.0066 0.00 (0.00 - Inf) — 0.00 (-Inf - Inf) —
Haplotypes within sex (n = 188, crude analysis)
Females Males
Haplotype Frequency OR (95% CI) P-value OR (95% CI) P-value
1 0.4102 1.00 — 1.00 —
2 0.4003 0.43 (0.22–0.83) 0.013* 0.77 (0.40–1.49) 0.444
3 0.1829 0.60 (0.26–1.40) 0.237 0.82 (0.35–1.96) 0.665
Rare 0.0066 0.00 (0.00 - Inf) — 0.00 (0.00 - Inf) —
Sex within haplotypes (n = 188, crude analysis)
Females Males
Haplotype Frequency OR (95% CI) OR (95% CI) P-value
1 0.4102 1.00 0.63 (0.19–2.07) 0.457
2 0.4003 1.00 1.12 (0.55–2.30) 0.769
3 0.1829 1.00 0.87 (0.32–2.34) 0.796
Rare 0.0066 1.00 Inf
Table 8.
Haplotype interaction analysis with covariate sex for polymorphisms located in p300 (P9 and P10
polymorphisms). Haplotype frequency, Odds ratio (OR) and P-value in female and male populations.
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strikingly much higher value than the others. That is due to the fact that this
haplotype only occurred in the trans population.
4.3 Concordance of our findings with the literature about receptor coactivators
To our knowledge, no studies have been published about the role of steroid
receptor coactivators in the genetic basis of GI. Our data are in concordance with a
recent work that showed that the nuclear receptor coactivators, NCOA-1, NCOA-2
and p300, are essential for efficient ER transcriptional activity in the brain [33, 38].
Furthermore, NCOA-1 and NCOA-2 are distributed in several specific areas of the
brain in different proportions, such as the hypothalamus and the hippocampus,
showing at the same time, difference in the coupling with the ERs [38, 39]. These
differential interactions between NCOA-1 and NCOA-2 with the ER subtypes α
and β suggest that these brain regions have distinct expression pattern of co-
regulators, and understanding how nuclear receptor coactivators function with
various steroid receptors is critical to understanding how hormones act in different
brain regions.
Moreover, our results are also in concordance with the study of the functional
significance of the nuclear receptor coactivator NCOA-1 in the developing brain
[40]. The authors, Auger et al., investigated the consequence of reducing NCOA-1
protein during sexual differentiation of the brain, and reported that reducing this
protein interferes with the defeminizing actions of estrogen in neonatal rat brains.
Their data indicated that NCOA-1 expression is critically involved in the hormone-
dependent development of normal male reproductive behavior and brain morphol-
ogy. Thus, our data are in agreement with the results of Auger et al., [40] since the
polymorphic analysis of this coactivator showed significant differences when allelic
and genotypic frequencies and haplotypes analyses were carried out.
Our data are also in concordance with other studies about the critical role of
p300 and CREBBP in ERα transcription. p300 and CREBBP are two of multiple
secondary coactivators recruited by NCOA1, NCOA2 or NCOA3 to form a receptor-
coactivator complex that can promote chromatin remodeling and facilitate tran-
scriptional activation [35]. In our work, we found statistical significances in p300,
CREBBP, NCOA1 and NCOA2, but not in NCOA3.
Transcription by RNA polymerase II requires the coordinated action of multiple
factors such as DNA-binding factors, coactivators, chromatin remodeling, with the
basal transcriptional machinery. Futhermore, p300 and CREBBP, do not bind DNA
on their own, but they play an essential role in the transcription process mediated
by E2 [33, 41]. Thus, ERα functions cooperatively with p300 and CREBBP to
increase transcription [42]. Yi et al. [35] demonstrated the quaternary structure of
an active complex of DNA-bound ERα, steroid receptor coactivator, and p300 as
secondary coactivator. The structural model suggests that the ER binds the ERE-
DNA as a dimer and then recruits two NCOAs; these two coactivators, in turn,
secure one molecule of p300 to the complex through multiple contacts.
It is very important to maintain the nucleotide sequence of the genes encoding
the coactivators in order to maintain the interactions of the ER-E2 -NCOA -p300-
CREBBP complex and thus perform the genomic function of estrogens. Therefore,
our data are in concordance because finding significant polymorphisms in the
sample analyzed may result in ineffective or low effective interactions affecting the
E2 target genes involved in brain dimorphism.
In our work, we found 2/9 polymorphisms with statistically significant differ-
ences (P9 and P10) in p300 in the interaction analysis with covariate “sex”. This
implied differences in haplotype distribution according to sex, and thus, the haplo-
type 2 (T-A) (Table 8) only showed significant differences in the population
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assigned as females at birth. The other haplotypes did not show differences in the
distribution between cis and trans population, nor in males or females.
Based on experiments in rodents, it is believed that male sexual differentiation
of the brain is caused by androgens, after conversion to estrogens by the aromatase.
Moreover, observations in human subjects show that the direct effects of testoster-
one on the developing fetal brain and also during puberty, are of great importance
for the development of male gender identity [43]. However, the analysis of the
androgen coactivator NCOA-4 did not show any significant data.
Currently, it is still very difficult to interconnect molecular, brain, and behav-
ioral findings [44] due to the complex interactions among behavior, genes, hor-
mones, receptors and enzymes. But we must point out that MRI studies in people
with GI, show characteristic brain profiles [5]. Both trans populations (females and
males) share some common features: firstly, the involvement of the two ERs in
neurobiological origin [21] and, secondly, their cortex, in some regions, is thicker
than in cismen [5]. These observations support the hypothesis that transmen and
transwomen undergo an atypical developmental process with respect to the sexual
differentiation of their cortex [5], hypothetically, under the influence of brain
estrogens, androgens, their receptors and some of their coactivators.
4.4 Consistency of the findings with the current hypothesis of a multiplicity of
mechanisms involved in the complex “mosaic”model of the mammalian
brain
Finally, our data are also consistent with the current hypothesis about the
existence of a complex “mosaic” model of the mammalian brain [45], with a
multiplicity of mechanisms involved, allowing a variable degree of masculinization/
feminization within the brain. The simple model according to which testosterone
masculinizes the brain of men away from a predetermined female profile, has been
replaced by a complex model, according to which sexual effects on the brains of
women and men are exerted by a complex combination of behavior, genetic,
epigenetic and hormonal factors [45].
5. Conclusions
Based on the data presented here, we believe that it can be stated that there is a
genetic basis for GI. Thus, the coactivators, NCOA-1, NCOA-2 and p300-CREBBP
could be considered as candidates for increasing the list of potential “susceptibility”
genes for GI. Furthermore, our data continue to support the hypothesis that GI is a
multifactorial complex trait, involving intricate interactions among genes, steroids,
steroids receptors and coactivators.
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